Finasteride treatment alters MMP-2 and -9 gene expression and activity in the rat ventral prostate

International Journal of Andrology

Volumn 33, Issue 1, 2010, Pages

  Delella, Flávia K ^a,b   Justulin Jr , Luis A ^a,b   Felisbino, Sérgio L ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Apoptosis; Finasteride; Matrix metalloproteinase; Prostate; Zymography

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; GELATINASE A; GELATINASE B; MESSENGER RNA; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; GENE EXPRESSION; HORMONE DETERMINATION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; ZYMOGRAPHY;

ANDROGENS; ANIMALS; EXTRACELLULAR MATRIX; FINASTERIDE; GENE EXPRESSION; GENES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 74349112458     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2009.00970.x     Document Type: Article

References (50)

1. Andriole, G., Bostwick, D., Civantos, F., Epstein, J., Lucia, M. S., McConnell, J. Roehrborn, C. G. (2005) The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. Journal of Urology 174, 2098 2104.
2. Bass, R., Perry, B., Langenstroer, P., Thrasher, J. B., Dennis, K. L., Tawfik, O. Holzbeierlein, J. (2009) Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. Journal of Urology 181, 615 619.
3. Bratland, A., Ragnhildstveit, E., Bjørnland, K., Andersen, K., Mælandsmo, G. M., Fodstad, O., Saatcioglu, F. Ree, A. H. (2003) The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells. Clinical and Experimental Metastasis 20, 541 547.
4. Carvalho, R. F., Dariolli, R., Justulin Junior, L. A., Sugizaki, M. M., Okoshi, M. P., Cicogna, A. C., Felisbino, S. L. Dal Pai-Silva, M. (2006) Heart failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle. International Journal of Experimental Pathology 87, 437 443.
5. Chakraborti, S., Mandal, M., Das, S., Mandal, A. Chakraborti, T. (2003) Regulation of matrix metalloproteinases: an overview. Molecular and Cellular Biochemistry 253, 269 285.
6. Corradi, L. S., Góes, R. M., Carvalho, H. F. Taboga, S. R. (2004) Inhibition of 5α-reductase activity induces stromal remodeling and smooth muscle de-differentiation in adult gerbil ventral prostate. Differentiation 72, 198 208.
7. Felisbino, S. L., Justulin Junior, L. A., Carvalho, H. F. Taboga, S. R. (2007) Epithelial-stromal transition of MMP-7 immunolocalization in the rat ventral prostate following bilateral orchiectomy. Cell Biology International 31, 1173 1178.
8. George, F. W. (1997) Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5a-dihydrotestosterone during development of the male urogenital tract. Endocrinology 138, 871 877.
9. Glassman, D. T., Chon, J. K., Borkowski, A., Jacobs, S. C. Kyprianou, N. (2001) Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 46, 45 51.
10. Gohji, K., Fujimoto, N., Hara, I., Fujii, A., Gotoh, A., Okada, H. et al. (1998) Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. International Journal of Cancer 79, 96 101.
11. Hara, T., Miyazaki, H., Lee, A., Tran, C. P. Reiter, R. E. (2008) Androgen receptor and invasion in prostate cancer. Cancer Research 68, 1128 1135.
12. Jung, K., Krell, H. W., Ortel, B., Hasan, T., Romer, A., Schnorr, D., Loening, S. A. Lein, M. (2003) Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. Prostate 54, 206 211.
13. Knox, J. D., Wolf, C., McDaniel, K., Clark, V., Loriot, M., Bowden, G. T. Nagle, R. B. (1996) Matrilysin expression in human prostate carcinoma. Molecular Carcinogenesis 15, 57 63.
14. Koltz, L. Clarke, N. (2008) Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer. European Urology 53, 1079 1083.
15. Levi, E., Fridman, R., Miao, H. Q., Ma, Y. S., Yayon, A. Vlodavsky, I. (1996) Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proceedings of the National Academy of Sciences of the United States of America 93, 7069 7074.
16. Li, B. Y., Liao, X. B., Fujito, A., Thrasher, J. B., Shen, F. Y. Xu, P. Y. (2007) Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian Journal of Andrology 9, 41 50.
17. Liao, X., Thrasher, J. B., Pelling, J., Holzbeierlein, J., Sang, Q. X. Li, B. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656 1663.
18. Lichtinghagen, R., Musholt, P. B., Lein, M., Römer, A., Rudolph, B., Kristiansen, G., Hauptmann, S., Schnorr, D., Loening, S. A. Jung, K. (2002) Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. European Urology 42, 398 406. (Pubitemid 35175803)
19. Limaye, A. M., Desai, K. V., Chavalmane, A. K. Kondaiah, P. (2008) Regulation of mRNAs encoding MMP-9 and MMP-2, and their inhibitors TIMP-1 and TIMP-2 by androgens in the rat ventral prostate. Molecular and Cellular Endocrinology 294, 10 18.
20. Liotta, L. A., Steeg, P. S. Stetler-Stevenson, W. G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327 336.
21. Lokeshwar, B. L. (1999) MMP inhibition in prostate cancer. Annals of the New York Academy Sciences 878, 271 289.
22. Lucia, M. S., Epstein, J. I., Goodman, P. J., Darke, A. K., Reuter, V. E., Civantos, F. et al. (2007) Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute 99, 1375 1383.
23. Mannello, F., Luchetti, F., Falcieri, E. Papa, S. (2005) Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10, 19 24.
24. Matrisian, L. M. (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends in Genetics 6, 121 125.
25. McCawley, L. J. Matrisian, L. M. (2001) Matrix metalloproteinases: They're not just for matrix anymore Current Opinion in Cell Biology 13, 354 340.
26. Molinié, V., Ruffion, A., Allory, Y., Leroy, X., Cochand Priollet, B., Paraf, F. de la Taille, A. (2005) Is tumour grade applicable to finasteride-treated prostate cancer? Progrès en urologie: journal de l'Association française d'urologie et de la Société française d'urologie 15, 387 391.
27. Morgia, G., Falsaperla, M., Malaponte, G., Madonia, M., Indelicato, M., Travali, S. Mazzarino, M. C. (2005) Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urological Research 33, 44 50.
28. Page-McCaw, A., Ewald, A. J. Werb, Z. (2007) Maxtrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8, 221 233.
29. Nagle, R. B. (2004) Role of the extracellular matrix in prostate carcinogenesis. Journal of Cellular Biochemistry 91, 36 40.
30. Powell, W. C., Knox, J. D., Navre, M., Grogan, T. M., Kittelson, J., Nagle, R. B. Bowden, G. T. (1993) Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Research 53, 417 422.
31. Powell, W. C., Domann, F. E., Jr., Mitchen, J. M., Matrisian, L. M., Nagle, R. B. Bowden, G. T. (1996) Matrilysin expression in the involuting rat ventral prostate. Prostate 29, 159 168.
32. Prahalada, S., Rhodes, L., Grossman, S. J., Heggan, D., Keenan, K. P., Cukierski, M. A., Hoe, C. M., Berman, C. van Zwieten, M. J. (1998) Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor. Prostate 35, 157 164.
33. Rittmaster, R. S., Manning, A. P., Wright, A. S., Thomas, L. N., Whitefield, S. Norman, R. W. (1995) Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology 136, 741 748.
34. Rittmaster, R. S., Norman, R. W., Thomas, L. N. Rowden, G. (1996) Evidence for atrophy and apoptosis in the prostates of men given finasteride. The Journal of Clinical Endocrinology and Metabolism 81, 814 819.
35. Sáez, C., González-Baena, A. C., Japón, M. A., Giráldez, J., Segura, D. I., Miranda, G., Rodríguez-Vallejo, J. M., González-Esteban, J. Torrubia, F. (1998) Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression. Prostate 37, 84 90.
36. Sauer, C. G., Kappeler, A., Spath, M., Kaden, J. J., Michel, M. S., Mayer, D., Bleyl, U. Grobholz, R. (2004) Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Archiv: an international journal of pathology 444, 518 526.
37. Sehgal, I. Thompson, T. C. (1999) Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-β1 in human prostate cancer cell lines. Molecular Biology of the Cell 10, 407 416.
38. Semaan, M., Jovenin, N., Birembaut, P., Menard, J. Staerman, F. (2005) Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer. Progrès en urologie: journal de l'Association française d'urologie et de la Société française d'urologie 15, 250 254.
39. Shao, T. C., Kong, A., Marafelia, P. Cunningham, G. R. (1993) Effects of finasteride on the rat ventral prostate. Journal of Andrology 14, 79 86.
40. Sutton, M. T., Yingling, M., Vyas, A., Atiemo, H., Borkowski, A., Jacobs, S. C. Kyprianou, N. (2006) Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate 66, 1194 1202.
41. Thomas, L. N., Douglas, R. C., Lazier, C. B., Too, C. K., Rittmaster, R. S. Tindall, D. J. (2008) Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. European Urology 53, 244 252.
42. Thompson, I. M., Klein, E. A., Lippman, S. M., Coltman, C. A. Djavan, B. (2003) Prevention of prostate cancer with finasteride: US/European perspective. European Urology 44, 650 655.
43. Thompson, I. M., Lucia, M. S., Redman, M. W., Darke, A., La Rosa, F. G., Parnes, H. L., Lippman, S. M., Coltman, C. A. (2007) Finasteride decreases the risk of prostatic intraepithelial neoplasia. The Journal of Urology 178, 107 109.
44. Trudel, D., Fradet, Y., Meyer, F., Harel, F. Tetu, B. (2003) Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Research 63, 8511 8515.
45. Visse, R. Nagase, H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation Research 92, 827 829.
46. Wilson, M. J., Strasser, M., Vogel, M. M. Sinha, A. A. (1991) Calcium-dependent and calcium-independent gelatinolytic proteinase activities of the rat ventral prostate and its secretion: characterization and effect of castration and testosterone treatment. Biology of Reproduction 44, 776 785.
47. Wilson, M. J., Sellers, R. G., Wiehr, C., Melamud, O., Pei, D. Peehl, D. M. (2002) Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. Journal of Cellular Physiology 191, 208 216.
48. Wood, M., Fudge, K., Mohler, J. L., Frost, A. R., Garcia, F., Wang, M. Stearns, M. E. (1997) In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clinical & Experimental Metastasis 15, 246 258.
49. Yamashita, A., Hayashi, N., Sugimura, Y., Cunha, G. R. Kawamura, J. (1996) Influence of Diethylstilbestrol, Leuprolelin (a luteinizing hormone-releasing hormone analog), Finasteride (a 5α-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate. Prostate 29, 1 14.
50. Yu, Q. Stamenkovic, I. (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes & Development 14, 163 176.